Wang Chenwen, Chen Zixiong, Ni Wei, Wang Jiang, Zhou Wei
Department of Orthopedics, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Front Oncol. 2025 Mar 4;15:1555270. doi: 10.3389/fonc.2025.1555270. eCollection 2025.
MiR-136 is abnormally expressed in many types of metastatic tumors and is closely associated with tumor cell proliferation, apoptosis, invasion, and metastasis, indicating its important role in tumor development and progression. This review summarizes current knowledge regarding miR-136's molecular mechanisms, functional roles, and impact on chemotherapy in different human cancers.
A literature search was conducted in PubMed and Web of Science using "miR-136" and "metastatic tumors" as English keywords, and in CNKI and Wanfang databases using the same terms in Chinese. Studies related to miR-136 research in metastatic tumors and high-quality evidence from similar studies were included. Meta-analyses, dissertations, conference papers, low-quality articles, unavailable full-text articles, and republished articles were excluded.
This review synthesizes the current understanding of miR-136's role in various cancers, including osteosarcoma, gastric cancer, gallbladder cancer, esophageal cancer, prostate cancer, colorectal cancer, breast cancer, glioma, and thyroid cancer. miR-136 acts as a tumor suppressor by targeting various genes, including MTDH, PTEN, MAP2K4, MUC1, LRH-1, MIEN1, RASAL2, CYR61, and KLF7. It influences multiple signaling pathways, including the ERK/mitogen-activated protein kinase, Wnt/β-catenin, Ha-Ras, PI3K/Akt, Aurora-A kinase, nuclear factor-κB, and JNK pathways. Furthermore, miR-136 is involved in chemoresistance by modulating ROCK1, PPP2R2A, and the miR-136-Notch3 signaling axis.
MiR-136 demonstrates promising potential as a novel biomarker and therapeutic target in various human cancers. Further research is needed to fully elucidate its complex roles in cancer development, progression, and drug resistance, particularly regarding its potential in immunotherapy.
miR-136在多种转移性肿瘤中异常表达，且与肿瘤细胞的增殖、凋亡、侵袭和转移密切相关，表明其在肿瘤发生发展过程中发挥重要作用。本综述总结了目前关于miR-136在不同人类癌症中的分子机制、功能作用及对化疗影响的相关知识。
在PubMed和Web of Science数据库中以“miR-136”和“转移性肿瘤”作为英文关键词进行文献检索，在中国知网和万方数据库中以相同的中文关键词进行检索。纳入与转移性肿瘤中miR-136研究相关的文献以及来自类似研究的高质量证据。排除荟萃分析、学位论文、会议论文、低质量文章、无法获取全文的文章以及重复发表的文章。
本综述综合了目前对miR-136在多种癌症中作用的理解，这些癌症包括骨肉瘤、胃癌、胆囊癌、食管癌、前列腺癌、结直肠癌、乳腺癌、神经胶质瘤和甲状腺癌。miR-136通过靶向多种基因发挥肿瘤抑制作用，这些基因包括MTDH、PTEN、MAP2K4、MUC1、LRH-1、MIEN1、RASAL2、CYR61和KLF7。它影响多个信号通路，包括ERK/丝裂原活化蛋白激酶、Wnt/β-连环蛋白、Ha-Ras、PI3K/Akt、极光激酶A、核因子κB和JNK通路。此外，miR-136通过调节ROCK1、PPP2R2A和miR-136-Notch3信号轴参与化疗耐药。
miR-136在多种人类癌症中展现出作为新型生物标志物和治疗靶点的潜在前景。需要进一步研究以充分阐明其在癌症发生、发展和耐药中的复杂作用，特别是其在免疫治疗中的潜力。
